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Carmen Martınez1, Carlos Solano2, Christelle Ferra3, Antonia Sampol4, David Valcarcel5,
Jose Antonio Perez-Simon6 for the Spanish Group for Stem Cell Transplantation (Grupo
Espan˜ol de Trasplante Hemopoyetico y Terapia Celular)We conducted a phase II trial to investigate the safety and efficacy of alemtuzumab in treating steroid-
refractory acute graft-versus-host disease (aGVHD) grade II or higher after stem cell transplantation. Ten
adult patients (6 with aGVHD grade III and 4 with aGVHD grade IV) were included in the study. Nine patients
had gastrointestinal tract involvement, 7 had skin involvement, and 5 had liver involvement. Five patients
responded to treatment, 2 with complete response and 3 with partial response. Eight infectious events
(4 of grade 3-4) and 7 cytomegalovirus (CMV) reactivations were observed. Six patients had grade 3-4
cytopenia. All 10 patients died (7 resulting from aGVHD progression, 2 from severe infection, and 1 from
to leukemia relapse), at a median of 40 days (range, 4 to 88 days) after alemtuzumab treatment. Overall,
our findings suggest that steroid-refractory aGVHD may be improved by treatment with alemtuzumab,
but that this treatment does not overcome the dismal prognosis of patients with severe aGVHD, demon-
strating the need for alternative therapies to treat this complication.
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Acute graft-versus-host disease (aGVHD) remains
amajor problem in allogeneic stem cell transplantation
(SCT), especially in patients who do not respond to
standard initial treatment with corticosteroids [1,2].
Steroid-refractory aGVHD is associated with a high
rate of morbidity and mortality, primarily from infec-
tion and/or multiorgan failure. Although various
agents for treating steroid-refractory aGVHD have
been tested, including high-dose steroids, antithymo-1Institute of Hematology and Oncology, Hematology
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6/j.bbmt.2009.01.014cyte globulin (ATG), mycophenolate mofetil (MMF),
tacrolimus, sirolimus, etanercept, pentostatin, and
several monoclonal antibodies (mAb), none has been
established as an effective salvage therapy [1,2].
Alemtuzumab (Campath-1H) is a humanized, un-
conjugated IgG1 kappa mAb that is specific for
CD52 receptors present on mature T and B lympho-
cytes, monocytes, monocyte-derived dendritic cells
(DCs), macrophages, and eosinophils [3,4]. It is well
known that the induction of aGVHD requires the pre-
sentation of host antigens to donor T cells by antigen-
presenting cells (APCs), such as DCs [5-8]. It also is
known that alemtuzumab prevents the development
of aGVHD and chronic GVHD (cGVHD) in SCT
by depleting T cells and DCs from both the donor
and the recipient [9-13]. Little data are available on
the efficacy of alemtuzumab for treating established
aGVHD, however. Here we report a prospective clin-
ical phase II trial conducted to evaluate the safety and
efficacy of alemtuzumab as salvage treatment for
patients with aGVHD failing primary steroid therapy.METHODS
Eligibility Criteria
This study was a multicenter phase II trial. The pri-
mary endpoint was overall response rate; secondary639
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transplantation lymphoproliferative disorders, and over-
all survival (OS). Patients were eligible if they were aged
$18 years, had undergone allogeneic SCT from either
a sibling or unrelated donor (matched or mismatched,
bone marrow or peripheral blood stem cells [PBSCs],
with a myeloablative or reduced-intensity conditioning
[RIC] regimen), and had a diagnosis of grade II or higher
steroid-refractory aGVHD. Patients who had an uncon-
trolled infection or a relapse of primary hematologic dis-
ease, had received alemtuzumab as part of GVHD
prophylaxis 30 days before the diagnosis of steroid-re-
fractory aGVHD, or had been treated with another sav-
age therapy were excluded from this study. Ethical
approval was obtained from each participating institu-
tion before the trial began. Every participant provided
written informed consent before entering into the study.
Diagnosis of Steroid-Refractory aGVHD and
Evaluation of Response
The assessment and grading of aGVHD were
based primarily on clinical findings. Diagnosis was
supported by skin, liver, or gastrointestinal (GI) tract
biopsy results whenever indicated and clinically possi-
ble. Symptoms were graded based on standard clinical
criteria and on the International Bone Marrow Trans-
plant Registry severity index [14-16]. Steroid-refrac-
tory aGVHD was defined as progression of aGVHD
in the first 72 hours, lack of improvement after 7
days of steroid therapy at a dosage of 2 mg/kg/day,
or incomplete response after 14 days of this steroid
therapy. Patients who achieved a complete response
(CR) or a partial response (PR) after steroid therapy
and experienced a relapse with the first taper of
steroids also were eligible for the study.
Response to alemtuzumab therapy was evaluated
and recorded prospectively on days 7, 14, 21, and 28,
and at the last follow-up after initiation of therapy. Or-
gan stage scores, overall clinical grade, and relevant
differential diagnosis were recorded at each evaluation.
CR was defined as the complete resolution of all
aGVHD symptoms in all organs. To be considered
a CR, this score had to be maintained for 28 days.
PR was defined as durable ($ 28 more days) improve-
ment in aGVHD stage in all initial target organs with-
out complete resolution and without worsening in any
other aGVHD target organ. No response (NR) was
defined as maintenance of the same grade of aGVHD
or progression of aGVHD in any organ. Progression
was defined as worsening aGVHD in one or more
organs with or without amelioration in any organ.
Alemtuzumab Treatment and Anti-Infective
Prophylaxis
Alemtuzumab was administered i.v. at a dose of 10
mg/day for 5 consecutive days, followed by 10 mg/dayonce weekly on days 8, 15, and 22 if CR was not
achieved. Acetaminophen, diphenhydramine, and
methylprednisolone were given as prophylaxis for the
secondary effects of alemtuzumab. The administration
of cyclosporine (CsA) and/or MMF continued during
the alemtuzumab treatment, whereas corticosteroids
were slowly tapered in those patients achieving re-
sponse (2 mg/kg on days 1 to 7, 1.5 mg/kg on days 8
to 15, and a 10% reduction every week thereafter).
Anti-infective prophylaxis was administered
according to the policy of each individual center; how-
ever, the following drugs were strongly recommended:
trimethoprim-sulfamethoxazol or nebulized pentami-
dine for Penumocystis jiroveci pneumonia; fluconazol,
voriconazol, or itraconazol for fungal infections; and
acyclovir for herpes virus reactivation. Cytomegalovi-
rus (CMV) infection was monitored once or twice
weekly by CMV pp65 antigenemia and/or quantitative
CMV polymerase chain reaction testing; if the results
were positive, then the patient was treated preemp-
tively with gancyclovir, valgancyclovir, or foscarnet.RESULTS
Patient Characteristics
Ten patients from 6 Spanish centers were enrolled
in this trial between March 2007 and April 2008. Pa-
tient characteristics are summarized in Table 1. All pa-
tients received peripheral blood as the stem cell source,
and 6 received allogeneic SCT from unrelated donors.
GVHD prophylaxis consisted of CsA in combination
with methotrexate (MTX) for the patients receiving
a myeloablative conditioning regimen (n 5 3) or in
combination with MMF for those receiving a fludara-
bine (Flu)-based RIC regimen (n 5 7). The median
time from allogeneic SCT to diagnosis of aGVHD
was 27.5 days (range, 9 to 144 days). Two 2 patients de-
veloped acute manifestations of GVHD beyond day
100 posttransplantation. All patients had severe
aGVHD (6 with grade III and 4 with grade IV). Nine
patients had GI tract involvement, 7 had skin involve-
ment, and 5 had liver involvement. Eight patients had
involvement of 2 or 3 organs (Table 2). Nine patients
received alemtuzumab therapy because of a failure of
steroid therapy according to the definition of refractory
aGVHD, and only 1 patient received alemtuzumab be-
cause of aGVHDflare after tapering of steroid therapy.
Themedian time from diagnosis of aGVHD to the ini-
tiation of alemtuzumab therapy was 8 days (range, 4 to
22 days). One patient received only the first 4 daily
doses of alemtuzumab, because of aGVHD progres-
sion and death. Nine patients received at least the first
5 doses of alemtuzumab; 4 received 6 doses, and 2 com-
pleted the scheduled treatment of 8 doses. The primary
reasons for incomplete treatment were progression of
aGVHD and clinical impairment.
Table 1. Patient Characteristics
Characteristic n
Age, years, median (range) 57 (19-65)
Sex, females/males 3/7
Diagnosis
Acute leukemias 4
Lymphoproliferative disorders 6
Donor
HLA-identical sibling 4
HLA-identical unrelated 5
HLA-mismatched unrelated 1
Conditioning regimen
Myeloablative 3
Reduced intensity 7
Source of stem cells
Peripheral blood 10
GVHD grade
III/IV 6/4
B/C/D 3/2/5
Organs involved
Skin 7
GI 9
Liver 5
Eastern Cooperative
Oncology Group (ECOG) score
1-2 5
3-4 3
Not reported 2
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Onepatient died of gut and hepatic aGVHDonday
4 after initiation of alemtuzumab therapy and could not
be evaluated for response. Two CRs and 3 PRs were
observed, for a clinical response rate of 55%. The 2 pa-
tients who achieved CR died, 1 of Klebsiella pneumoniae
sepsis at 43 days after alemtuzumab treatment and 1 of
acutemyelogenous leukemia (AML) relapse at 188 days
after alemtuzumab treatment. The 3 patients who
achieved PR also died, 2 from aGVHD and multiorgan
failure at 29 and 93 days after alemtuzumab treatment
and 1 from invasive fungal infection at 44 days after
alemtuzumab treatment (Table 2). No correlation was
observed between the number of doses of alemtuzumab
and response (t-test and linear regression; P . .05);Table 2. Results of Alemtuzumab Treatment in Patients with Ster
Patient Donor
Days to Initiation
of Alemtuzumab*
aGVHD
Stage
Skin
Stage
Liver
Stage
GI
Stage
1 MUD 4 III/C + + +++
2 MUD 22 IV/D 0 0 ++++
3 MUD 6 IV/D 0 ++++ 0
4 MSD 10 III/B + 0 ++
5 MMUD 12 IV/D ++++ 0 +
6 MSD 4 III/D 0 + ++++
7 MUD 8 III/B ++ 0 ++
8 MSD 8 III/B ++ ++ +
9 MUD 9 IV/D ++ 0 ++++
10 MSD 5 III/C ++ ++ +++
aGVHD indicates acute graft-versus-host disease; MUD, matched unrelated do
PD, progressive disease; NE, not evaluable; NR, no response; IFI, invasive fung
*Time from diagnosis of aGVHD to initiation of alemtuzumab.
†Time from alemtuzumab treatment to death.however, the small number of patients included in this
study, and the early death of some, precludes us from
drawing any conclusions regarding alemtuzumab dos-
ing. All nonresponding patients died of aGVHD pro-
gression after a median of 20 days (range, 15 to 42
days). A total of 8 infectious events (4 of which
were grade 3-4) and 7 episodes of CMV reactivation
were reported.Grade3-4 anemia, neutropenia, and lym-
phopenia occurred in one patient each, and thrombocy-
topenia occurred in 2 patients. One patient presented
withgrade3pancytopenia.Nopatienthada lymphopro-
liferative disorder. After obtaining these results, we
decided to close the trial prematurely.DISCUSSION
To date, only a few reports have investigated the
efficacy of alemtuzumab in treating steroid-refractory
aGVHD. Carella et al. [17] reported successful treat-
ment of steroid-refractory aGVHDwith alemtuzumab
in 3 patients. One of these patients, a 53-year-old fe-
male with grade II-III aGVHD of the skin, GI tract,
and liver, treated with 4 doses of alemtuzumab, dem-
onstrated improvement in all organs evaluated; how-
ever, she died of renal and cardiac failure (with the
renal failure attributed to ganciclovir therapy) on day
106 after undergoing SCT. The second patient,
a 46-year-old male with grade III-IV aGVHD involv-
ing the GI tract and liver, achieved CR after 4 doses of
alemtuzumab. The third patient, a 44 year-old female,
developed grade III aGVHD of the liver and achieved
PR after 5 doses of alemtuzumab. Wandroo et al. [18]
reported 2 patients, with steroid-refractory grade IV
aGVHD with liver involvement, who responded to 5
doses of alemtuzumab (10 mg/day).
To the best of our knowledge, to date only one pro-
spective study has addressed the use of alemtuzumab to
treat steroid-refractory aGVHD. Gomez-Almaguer
et al. [19] reported 18 patients treated with alemtuzu-
mab administered s.c. at a dose of 10 mg/day for 5oid-Refractory aGVHD
Response
to Alemtuzumab Death Cause
Overall
Survival†
PD Yes GVHD 16
CR Yes Bacterial infection 43
PR Yes GVHD + liver failure 39
PD Yes GVHD 24
PR Yes GVHD + multiorgan failure 93
NE Yes GVHD 4
PD Yes GVHD 42
PR Yes IFI 44
NR Yes GVHD + IFI 15
CR Yes Leukemic relapse 188
nor; MSD, matched sibling donor; MMUD, mismatched unrelated donor;
al infection.
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8 had grade III aGVHD, and 2 had grade IV aGVHD.
The main organs involved were the liver in 4 patients,
GI tract in 5, skin in 3, skin and liver in 3, and skin
and GI tract in 3. The overall response rate was 83%
and the CR rate was 33%, higher than that found in
our trial. Ten of the 15 patients who responded to
alemtuzumab therapy were alive at a median follow-
up of 11 months (range, 3 to 24 months). In our study,
55% of the patients responded to alemtuzumab, but all
of the patients because of to aGVHD progression, in-
fection, or relapse. Several differences between our
study and that of Gomez-Almaguer et al. [19] may ac-
count for these discrepant results; for example, in our
trial, the proportion of patients receiving stem cells
from an unrelated donor and developing steroid-
refractory aGVHD within the first 100 days after
SCT was higher (60% vs 80%), and the patients were
older (median age, 57 years [range, 19 to 65 years] vs
37 years [range, 1 to 59 years]) and had more advanced
GVHD (grade III-IV, 100% vs 56%).
Overall, our findings suggest that although alem-
tuzumab therapy may improve steroid-refractory
aGVHD, it does not overcome the dismal prognosis
of patients with severe steroid-refractory aGVHD.
However, in view of the small number of patients re-
ported here, our findings do warrant further investiga-
tion of alemtuzumab in a larger patient group to better
define its application in this clinical situation.ACKNOWLEGMENTS
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